Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- Expert Panel Recommends Priority Measures Including Pediatric Drug Development for FY2013 Budget
July 23, 2012
- Mix of Differential Pricing and Generic Drug Use Promotion Policies Can Help Reduce Drug Expenditure: Prof. Sakamaki
July 23, 2012
- MHLW Study Group Launches Info Website on Epilepsy Treatment Facilities
July 23, 2012
- Vaccines Are Good Investments: Dr Warton of CDC
July 23, 2012
- Industry Representatives Express Concern over Large Reductions in Prices of Long-Listed Drugs at CSIMC
July 20, 2012
- Industry Figures Stress Positive Impact of Premium for Generic-Name Prescribing at CSIMC
July 20, 2012
- Cost-Effective Assessments to Be Limited to Technologies for Which Alternatives Are Available: CSIMC
July 19, 2012
- PAFSC’s 2nd Committee on Drugs to Review 2 Combination DPT-IPV Vaccines on July 20
July 19, 2012
- Establishment of Relief System for Victims of Health Damage Due to Anticancer Drugs Should Be Put Off: MHLW Study Group
July 17, 2012
- Draft Revitalization Strategy Calls for Screening of 100 Drug Seeds through Drug Discovery Support Network by FY2015
July 13, 2012
- PFSB Calls for Revisions of Package Inserts for 13 Products Including Ranmark, Lyrica
July 13, 2012
- Gov’t to Discuss Expansion of Japan-EC Mutual Recognition Agreement in Pharmaceutical Sector
July 12, 2012
- Health Minister Komiyama Takes Lead to Include Reference Price Systems in Policy-Screening Group’s Proposals
July 10, 2012
- MHLW’s Medical Innovation Promotion Office Sets Up Cross-Sectional Task Forces to Discover Innovative Anticancer Drugs
July 10, 2012
- Bill Payers, Healthcare Providers Fighting over Financial Resources from Price Cuts for Long-listed Drugs
July 10, 2012
- PAFSC Second Committee to Review Products Including Novartis’s Pulmonary Infection Treatment on July 20
July 10, 2012
- Council’s Action Plan for FY2013 Calls for Conducting 10 Kinds of Clinical Trials within 5 Years
July 9, 2012
- On-Site Strategy Consultations to Be Held in Kansai Region: MHLW
July 6, 2012
- Interest Shown in Development of 3 Unapproved Drugs/Indications Including Metyrosine
July 6, 2012
- PMDA to Use Science Committee to Help Strengthen Review System: Executive Director Utsumi
July 5, 2012
ページ
Japan’s health and finance ministers agreed late last year to go ahead with an “off-year” drug price revision in FY2027,…
The Japanese healthcare sector is experiencing rapid growth, demanding a highly skilled and diverse workforce. However, finding and attracting the best talent in this competitive market presents significant challenges.Enter AI. With the rise of AI-powered tools, healthcare organizations can revolutionize…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…